A Phase I Study of BR108 in Hematological Malignancies

NCT06018506 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

8

Enrollment

INDUSTRY

Sponsor class

Stopped Adjustment of Company R\&D strategy

Conditions

Hematologic Malignancy

Interventions

DRUG: BR108 injection

Sponsor

BioRay Pharmaceutical Co., Ltd.